

Carasent ASA

Second Quarter
and Half Year
2019 Results



CARRASENT



**OVERVIEW OF
SECOND
QUARTER 2019
CONSOLIDATED
RESULTS FOR
CARASENT ASA
(IN NOK AND
IFRS).**



Revenues of NOK 11,2 million as compared to no NOK 5,8 million during Q2-18.



Net income of NOK 0,3 million as compared to net loss of NOK 3,0 million during Q2-18.




Cash balances of NOK 7,2 million at June 30, 2019.

Evimeria EMR 2Q 2019

- Revenue of SEK 14,8 million *, an increase of 42 % as compared to Q2 2018
- EBITDA of SEK 3,4 million as compared to SEK 2,2 million during Q2 2018
- EBIT of SEK 2,6 million as compared to SEK 1,6 million during Q2 2018
- * Swedish GAAP and SEK


Revenues



Evimeria EMR 2Q 2019

- Signed 24 new clinics during the Second Quarter 2019, which is higher than previous year representing more than one new clinic per week
- Ended the second quarter with 360 active clinics
- Signed a contract with doktor.se, a leading Swedish online health care provider
- Occupational health service segment shows good traction and out of the 24 new clinics signed, 4 came from this segment.

Customers



Doktor.se


- On April 15th Evimeria EMR AB signed a contract with doktor.se, a leading Swedish online-doctor.
- Important breakthrough with a well-known provider in this fast growing market segment.
- The contract value is initially approx. SEK 2 million per year and doktor.se will be one of Evimeria biggest customers so far.



Evimeria EMR 2Q 2019

- The scalability of the business and delivery model continues to increase earnings
- Well in line with targets for 2019
- Short- and midterm market conditions seems to remain strong.
- Long term, Evimeria will accelerate investments to approach new markets and segments

EBITDA



Market
development and
accelerated
strategic expansion

The demand for Evimerias services and solutions remains strong

order bookings are good

forecast for 2019 is in the upper edge
of the benchmark that were given

early indications suggest a strong 2020

Evimeria has decided to accelerate investments

New segments

Geographically

Products and services

While part of our original
operational plan, we now
intend to do so at a faster
pace.

The above will also mitigate some of the known political long-term risk in the Swedish market over the next 3-5 years.

Growth and trends in the healthcare market



Three major drivers

The proportion of the population aged 60 or older

Medical progress and the ability to manage illness are contributing to an overall increased average lifetime

Chronic diseases, such as diabetes, obesity and certain cardiovascular diseases, are increasing and are treated over longer periods of time



The need for high-quality healthcare at lower cost to society has therefore never been greater.



Digitalization is transforming healthcare

The use of digital solutions is increasing availability to patients

Digital solutions also increase opportunities to share necessary and relevant information

Receive healthcare on a remote basis when doctors are available via chat or video,

Strategy going forward



Continue to invest in Evimeria EMR AB and Webdoc and expand in nearby and similar segments



Actively searching to expand geographical and/or service offering through partnerships or acquisitions within the health tech segment



Focus in Scandinavia (Nordics)